Oral l-citrulline malate in patients with idiopathic pulmonary arterial hypertension and Eisenmenger Syndrome: A clinical trial

Journal of Cardiology

Volumn 64, Issue 3, 2014, Pages 231-235

  Sharif Kashani, Babak ^a   Pour, Paritash Tahmaseb ^a   Malekmohammad, Majid ^b   Behzadnia, Neda ^c   Sheybani Afshar, Faezeh ^d   Fakhri, Mohammad ^d   Chaibakhsh, Samira ^e   Naghashzadeh, Farah ^a   Aidenlou, Salavan ^d  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d Shahid Beheshti University of Medical Sciences   (Iran)

^e SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Eisenmenger syndrome; Exercise capacity; Idiopathic pulmonary arterial hypertension; L Citrulline malate; Quality of life

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CITRULLINE; CITRULLINE MALATE; UNCLASSIFIED DRUG; BRAIN NATRIURETIC PEPTIDE; MALIC ACID DERIVATIVE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; EISENMENGER COMPLEX; EMOTIONAL STABILITY; EXERCISE; FATIGUE; FEMALE; FUNCTIONAL STATUS; HEALTH STATUS; HEARTBURN; HUMAN; LEG EDEMA; LUNG ARTERY PRESSURE; MALE; MICTURITION DISORDER; PAIN; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SHORT FORM 36; SOCIAL INTERACTION; TREATMENT DURATION; WALKING; WALKING DISTANCE; WELLBEING; ANALOGS AND DERIVATIVES; ARTERIAL PRESSURE; BLOOD; CLINICAL TRIAL; FAMILIAL PRIMARY PULMONARY HYPERTENSION; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PULMONARY ARTERY; TREATMENT OUTCOME; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; ARTERIAL PRESSURE; CITRULLINE; EISENMENGER COMPLEX; FAMILIAL PRIMARY PULMONARY HYPERTENSION; FEMALE; HUMANS; MALATES; MALE; NATRIURETIC PEPTIDE, BRAIN; PULMONARY ARTERY; QUALITY OF LIFE; TREATMENT OUTCOME; WALKING; YOUNG ADULT;

EID: 84926261640     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2014.01.003     Document Type: Article

References (38)

1. Zuckerbraun B.S., George P., Gladwin M.T. Nitrite in pulmonary arterial hypertension: therapeutic avenues in the setting of dysregulated arginine/nitric oxide synthesis signaling. Cardiovasc Res 2011, 89:542-552.
2. McKnight G.M., Smith L.M., Drummond R.S., Duncan C.W., Golden M., Benjamin N. Chemical synthesis of nitric oxide in the stomach from dietary nitrate in humans. Gut 1997, 40:211-214.
3. Zweier J.L., Wang P., Samouilov A., Kuppusamy P. Enzyme-independent formation of nitric oxide in biological tissues. Nat Med 1995, 1(August (8)):804-809.
4. Romero M., Platt D.H., Caldwell R.B., Caldwell R.W. Therapeutic use of citrulline in cardiovascular disease. Cardiovasc Drug Rev 2006, 24:275-290.
5. Kaye D.M., Parnell M.M., Ahlers B.A. Reduced myocardial and systemic l-arginine uptake in heart failure. Circ Res 2002, 91(December (12)):1198-1203.
6. Moncada S., Higgs A. Mechanisms of disease: the l-arginine-nitric oxide pathway. N Engl J Med 1993, 329:2002-2012.
7. Rubin L.J. Primary pulmonary hypertension. N Engl J Med 1997, 336:111-117.
8. Suzuki K., Akashi Y.J., Manabe M., Mizukoshi K., Kamijima R., Kou S., Takai M., Izumo M., Kida K., Yoneyama K., Omiya K., Yamasaki Y., Yamada H., Nobuoka S., Miyake F. Simple exercise echocardiography using a Master's two-step test for early detection of pulmonary arterial hypertension. J Cardiol 2013, 62(September (3)):176-182.
9. Simonneau G., Galiè N., Speich L.J.R., Beghetti M., Rich S., Fishman A. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004, 43(June (12 Suppl. S)):5S-12S.
10. Kidd L., Driscoll D., Gersony W. Second natural history study of congenital heart defects. Circulation 1993, 87:138-151.
11. Morse J.H., Barst R.J., Fotino M. Familial pulmonary hypertension: immunogenetic findings in four Caucasian Kindreds. Am Rev Respir Dis 1992, 145:787-792.
12. Romero M.J., Platt D.H., Caldwell R.B., Caldwell R.W. Therapeutic use of citrulline in cardiovascular disease. Cardiovasc Drug Rev 2006, 24:275-290.
13. Yao A. Recent advances and future perspectives in therapeutic strategies for pulmonary arterial hypertension. J Cardiol 2012, 60:344-349.
14. Russell A.M., Zwass M.S., Fineman J.R., Balea M., Rouine-Rapp K., Brook M., Hanley F.L., Silverman N.H., Cahalan M.K. The effects of inhaled nitric oxide on postoperative pulmonary hypertension in infants and children undergoing surgical repair of congenital heart disease. Anesth Analg 1998, 87:46-51.
15. Rich S., Dantzker D.R., Ayres S.M., Bergofsky E.H., Brundage B.H., Detre K.M., Fishman A.P., Goldring R.M., Groves B.M., Koerner S.K. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987, 107:216-223.
16. Berger M., Haimowitz A., Van Tosh A., Berdoff R.L., Goldberg E. Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound. J Am Coll Cardiol 1985, 6:359-365.
17. Kim N.H.S. Diagnosis and evaluation of the patient with pulmonary hypertension. Cardiol Clin 2004, 22:367-373.
18. Goodwin B.L., Solomonson L.P., Eichler D.C. Argininosuccinate synthase expression is required to maintain nitric oxide production and cell viability in aortic endothelial cells. J Biol Chem 2004, 279:18353-18360.
19. Summar M.L., Gainer J.V., Pretorius M., Malave H., Harris S., Hall L.D., Weisberg A., Vaughan D.E., Christman B.W., Brown N.J. Relationship between carbamoyl-phosphate synthetase genotype and systemic vascular function. Hypertension 2004, 43:186-191.
20. Barr F.E., Tirona R.G., Taylor M.B., Rice G., Arnold J., Cunningham G., Smith H.A., Campbell A., Canter J.A., Christian K.G., Drinkwater D.C., Scholl F., Kavanaugh-McHugh A., Summar M.L. Pharmacokinetics and safety of intravenously administered citrulline in children undergoing congenital heart surgery: potential therapy for postoperative pulmonary hypertension. J Thorac Cardiovasc Surg 2007, 134:319-326.
21. Smith H.A., Canter J.A., Christian K.G., Drinkwater D.C., Scholl F.G., Christman B.W., Rice G.D., Barr F.E., Summar M.L. Nitric oxide precursors and congenital heart surgery: a randomized controlled trial of oral citrulline. J Thorac Cardiovasc Surg 2006, 132:58-65.
22. Miyamoto S., Nagaya N., Satoh T., Kyotani S., Sakamaki F., Fujita M., Nakanishi N., Miyatake K. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension: comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000, 161:487-492.
23. Galiè N., Seeger W., Naeije R., Simonneau G., Rubin L.J. Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2004, 43(Suppl. 12):81S-88S.
24. Rubin L.J., Badesch D.B., Barst R.J., Galiè N., Black C.M., Keogh A., Pulido T., Frost A., Roux S., Leconte I., Landzberg M., Simonneau G. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002, 346:896-903.
25. Simonneau G., Barst R.J., Galiè N., Naeije R., Rich S., Bourge R.C., Keogh A., Oudiz R., Frost A., Blackburn S.D., Crow J.W., Rubin L.J. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002, 165:800-804. Treprostinil Study Group.
26. Olschewski H., Simonneau G., Galiè N., Higenbottam T., Naeije R., Rubin L.J., Nikkho S., Speich R., Hoeper M.M., Behr J., Winkler J., Sitbon O., Popov W., Ghofrani H.A., Manes A., et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002, 347:322-329.
27. Barst R.J., Rubin L.J., Long W.A., McGoon M.D., Rich S., Badesch D.B., Groves B.M., Tapson V.F., Bourge R.C., Brundage B.H., Koerner S.K., Langleben D., Keller C.A., Murali S., Uretsky B.F., et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996, 334:296-301.
28. Galiè N., Ghofrani H.A., Torbicki A., Barst R.J., Rubin L.J., Badesch D., Fleming T., Parpia T., Burgess G., Branzi A., Grimminger F., Kurzyna M., Simonneau G. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005, 353:2148-2157.
29. Rector T.S., Bank A.J., Mullen K.A., Tschumperlin L.K., Sih R., Pillai K., Kubo S.H. Randomized, double-blind, placebo-controlled study of supplemental oral l-arginine in patients with heart failure. Circulation 1996, 93(June (12)):2135-2141.
30. Hambrecht R., Hilbrich L., Erbs S., Gielen S., Fiehn E., Schoene N., Schuler G. Correction of endothelial dysfunction in chronic heart failure: additional effects of exercise training and oral l-arginine supplementation. J Am Coll Cardiol 2000, 35:706-713.
31. Kaneko F.T., Arroliga A.C., Dweik R.A., Comhair S.A., Laskowski D., Oppedisano R., Thomassen M.J., Erzurum S.C. Biochemical reaction products of nitric oxide as quantitative markers of primary pulmonary hypertension. Am J Respir Crit Care Med 1998, 158:917-923.
32. Archer S.L., Djaballah K., Humbert M., Weir E.K., Fartoukh M., Dall'avasantucci J., Mercier J., Simonneau G., Dinh-xuan A.T. Nitric oxide deficiency in fenfluramine- and dexfenfluramine-induced pulmonary hypertension. Am J Respir Crit Care Med 1998, 158:1061-1067.
33. Cooper C.J., Landzberg M.J., Anderson T.J., Charbonneau F., Creager M.A., Ganz P., Selwyn A.P. Role of nitric oxide in the local regulation of pulmonary vascular resistance in humans. Circulation 1996, 93:266-271.
34. Creager M.A., Gallagher S.J., Girerd X.J., Coleman S.M., Dzau V.J., Cooke J.P. l-Arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest 1992, 90:1248-1253.
35. Drexler H., Fischell T.A., Pinto F.J., Chenzbraun A., Botas J., Cooke J.P., Alderman E.L. Effect of l-arginine on coronary endothelial function in cardiac transplant recipients. Circulation 1994, 89:1615-1623.
36. Koifman B., Wollman Y., Bogomolny N., Chernichowsky T., Finkelstein A., Peer G., Scherez J., Blum M., Laniado S., Iaina A., Keren G. Improvement of cardiac performance by intravenous infusion of l-arginine in patients with moderate congestive heart failure. J Am Coll Cardiol 1995, 26:1251-1256.
37. Nagaya N., Nishikimi T., Okano Y., Uematsu M., Satoh T., Kyotani S., Kuribayashi S., Hamada S., Kakishita M., Nakanishi N., Takamiya M., Kunieda T., Matsuo H., Kangawa K. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol 1998, 31:202-208.
38. Nagaya N., Nishikimi T., Uematsu M., Satoh T., Kyotani S., Sakamaki F., Kakishita M., Fukushima K., Okano Y., Nakanishi N., Miyatake K., Kangawa K. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000, 102:865-870.